The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after ...
Pembrolizumab联合标准化疗方案治疗晚期非鳞非小细胞肺癌的疗效 1文献来源Langer CJ,Gadgeel SM,Borghaei H,et al.Carboplatin and Pemetrexed with or without Pembrolizumab for advanced,non-squamous non-small-cell lung cance... 范云,张嘉涛 - 《循证医学》 被引量: 1发表: 2017年 Comparative efficacy and...
Carboplatin/pembrolizumab/pemetrexed. Reactions Weekly 1779, 59 (2019). https://doi.org/10.1007/s40278-019-71323-1 Download citation Published16 November 2019 Issue DateNovember 2019 DOIhttps://doi.org/10.1007/s40278-019-71323-1 Access this article Log in via an institution Subscribe and save...
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Summary Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves eff...
Eligible patients were randomized 1:1 to 4 to 6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n = 205 and 207, respectively). Total camrelizumab exposure was up to 2 yea...
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol (2016)View more references Cited by (360) Gemcitabine and cisplatin plus durvalumab with or without tremelim...
In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in...
Pembrolizumab monotherapy or immune checkpoint inhibitor with platinum and pemetrexed combination chemotherapy are the standard therapies for patients with nonsquamous non-small-cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50%. However, there ar...
pembrolizumab plus pemetrexed (Eli Lilly and Company, Indianapolis, IN, USA) and car- boplatin (Hospira, Lake Forest, IL, USA) is indicated for first-line treatment of patients with metastatic non-squamous cell but not squamous cell NSCLC.9 Therefore, while immunotherapy agents have recently beg...
Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC). Patients and methods Eligible patients...